A phase II study of M6620 and irinotecan in TP53 mutant gastric and gastroesophageal junction (GEJ) adenocarcinoma patients (pts) INCT036413131.

被引：0

作者：

Das, Satya

Whisenant, Jennifer

Doyle, Austin

Allegra, Carmen Joseph

Berlin, Jordan

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] NCI, Rockville, MD USA

[3] NSABP Fdn, Gainesville, FL USA

[4] Univ Florida, Gainesville, FL USA

[5] Vanderbilt Univ, Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.TPS175

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS175

引用

页数：2

共 50 条

[41] A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study
Cohen, Deirdre Jill
Christos, Paul J.
Sparano, Joseph A.
Kindler, Hedy Lee
Catenacci, Daniel Virgil Thomas
Bekaii-Saab, Tanios B.
Tahiri, Sanaa
Janjigian, Yelena Yuriy
Gibson, Michael K.
Chan, Emily
Rajdev, Lakshmi
Urba, Susan
Wade, James Lloyd
Kozuch, Peter
Love, Erica
Vandris, Katherine
Takebe, Naoko
Hochster, Howard S.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[42] Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).
Bang, Yung-Jue
Golan, Talia
Lin, Chia-Chi
Kang, Yoon-Koo
Wainberg, Zev A.
Wasserstrom, Heather
Jin, Jin
Mi, Gu
McNeely, Samuel
Laing, Naomi
Goff, Laura Williams
Fu, Siqing
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[43] A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174).
Eads, Jennifer Rachel
Weitz, Michelle
Gibson, Michael K.
Rajdev, Lakshmi
Khullar, Onkar, V
Lin, Steven H.
Gatsonis, Constantine
Wistuba, Ignacio Ivan
Sanjeevaiah, Aravind
Benson, Al Bowen
Bahary, Nathan
Spencer, Kristen Renee
Saba, Nabil F.
Hamilton, Stanley R.
Staley, Charles A.
Chakravarthy, Anuradha Bapsi
Wong, Terence Z.
O'Dwyer, Peter J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[44] Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).
Catenacci, Daniel V. T.
Park, Haeseong
Lockhart, A. Craig
Gold, Philip Jordan
Enzinger, Peter C.
Nordstrom, Jeffrey L.
Hong, Sam
Hochster, Howard S.
Kelly, Ronan Joseph
Uronis, Hope Elizabeth
Bendell, Johanna C.
Oh, Sang Cheul
Park, Se Hoon
Kim, Yeul Hong
Kang, Yoon-Koo
Lee, Keun-Wook
Ng, Matthew C. H.
Wigginton, Jon M.
Davidson-Moncada, Jan Kenneth
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[45] Tolerability and quality-of-life (QoL) results from the phase REGARD study: Ramucirumab versus placebo in patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma
Chau, I.
Passalacqua, R.
Zalcberg, J. R.
Fuchs, C. S.
Liepa, A. M.
Hsu, Y.
Schwartz, J. D.
Koshiji, M.
Tabernero, J.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S615 - S615
[46] Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)-ILUSTRO Cohort 3.
Klempner, Samuel J.
Ajani, Jaffer A.
Al-Batran, Salah-Eddin
Bang, Yung-Jue
Catenacci, Daniel V. T.
Enzinger, Peter C.
Ilson, David H.
Kim, Sunnie
Lordick, Florian
Shah, Manish A.
Shitara, Kohei
Arozullah, Ahsan
Park, Jung Wook
Raizer, Jeffrey J.
Van Cutsem, Eric
Xu Rui-Hua
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[47] A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
Menglong Zhou
Wang Yang
Yan Xuan
Wei Zou
Yaqi Wang
Zhiyuan Zhang
Jing Zhang
Miao Mo
Changming Zhou
Yuan Liu
Wenming Zhang
Zhaozhen Zhang
Yiping He
Weiwei Weng
Cong Tan
Lei Wang
Dan Huang
Weiqi Sheng
Huanhuan Li
Hui Zhu
Yan Wang
Lijun Shen
Hui Zhang
Juefeng Wan
Guichao Li
Hua Huang
Yanong Wang
Zhen Zhang
Xiaowen Liu
Fan Xia
BMC Cancer, 22
[48] A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
Zhou, Menglong
Yang, Wang
Xuan, Yan
Zou, Wei
Wang, Yaqi
Zhang, Zhiyuan
Zhang, Jing
Mo, Miao
Zhou, Changming
Liu, Yuan
Zhang, Wenming
Zhang, Zhaozhen
He, Yiping
Weng, Weiwei
Tan, Cong
Wang, Lei
Huang, Dan
Sheng, Weiqi
Li, Huanhuan
Zhu, Hui
Wang, Yan
Shen, Lijun
Zhang, Hui
Wan, Juefeng
Li, Guichao
Huang, Hua
Wang, Yanong
Zhang, Zhen
Liu, Xiaowen
Xia, Fan
BMC CANCER, 2022, 22 (01)
[49] Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB)
Tabernero, Josep
Hoff, Paulo Marcelo
Shen, Lin
Ohtsu, Atsushi
Yu, Ron
Eng-Wong, Jennifer
Kang, Yoon-Koo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[50] A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results
Herbst, Roy S.
Bendell, Johanna C.
Isambert, Nicolas
Calvo, Emiliano
Santana-Davila, Rafael
Cassier, Philippe
Perez-Gracia, Jose Luis
Yang, Jing
Rege, Jessicca
Ferry, David
Mi, Gu
Chau, Ian
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →